Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900865 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL29257688 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL2067136 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL3293988 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL1900915 | 1.00 | EPHX1 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL13416816 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL16316581 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5509761 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL19538503 | 0.82 | TP53 (0.48) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL14299180 | 0.82 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239988-A | Preparation method and application of heterochiral binuclear Ir (III) metal-organic double-helix structure compound | 大连理工大学 | 2024-06-25 | — | — | CN | claimed |
| US-20240166814-A1 | POLYESTERAMIDE RESIN, MANUFACTURING METHOD OF THE SAME, AND BIAXIALLY STRETCHED FILM INCLUDING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2024-05-23 | — | — | US | claimed |
| CN-114437136-A | Preparation method and application of thiourea functionalized multi-chiral dual-core Ir (III) metal-organic double helix structure | 大连理工大学 | 2022-05-06 | — | — | CN | claimed |
| CN-100584460-C | Catalyst for asymmetric (transfer) hydrogenation | DSM IP ASSETS BV | 2010-01-27 | — | — | CN | claimed |
| CN-1974010-A | Catalyst for asymmetric (transfer) hydrogenation | DSM IP ASSETS BV (NL) | 2007-06-06 | — | — | CN | claimed |
| CN-1827214-A | Catalyst for asymmetric (transfer) hydrogenation | DSM IP ASSETS BV (NL) | 2006-09-06 | — | — | CN | claimed |
| US-20240166814-A1 | POLYESTERAMIDE RESIN, MANUFACTURING METHOD OF THE SAME, AND BIAXIALLY STRETCHED FILM INCLUDING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2024-05-23 | — | — | US | disclosed |
| WO-2024085502-A1 | RESIN COMPOSITION COMPRISING POLYESTERAMIDE RESIN AND MOLDED ARTICLE THEREOF | 에스케이케미칼 주식회사 | 2024-04-25 | — | — | WO | disclosed |
| CN-114437136-B | Preparation method and application of thiourea functionalized multi-chiral binuclear Ir (III) metal-organic double helix structure | 大连理工大学 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022235008-A1 | POLYESTERAMIDE RESIN, MANUFACTURING METHOD THEREOF, AND BIAXIALLY STRETCHED FILM INCLUDING SAME | 에스케이케미칼 주식회사 | 2022-11-10 | — | — | WO | disclosed |
| CN-114437136-A | Preparation method and application of thiourea functionalized multi-chiral dual-core Ir (III) metal-organic double helix structure | 大连理工大学 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021223156-A1 | DIBORON GLYCOL ESTER, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2021-11-11 | — | — | WO | disclosed |
| EP-1970360-B1 | Method for producing alcohols | TAKASAGO PERFUMERY CO LTD (JP) | 2016-08-31 | — | — | EP | disclosed |
| CN-1827214-A | Catalyst for asymmetric (transfer) hydrogenation | DSM IP ASSETS BV (NL) | 2006-09-06 | — | — | CN | disclosed |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-02 | — | — | US | disclosed |
| EP-1136475-B1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | disclosed |
| EP-1136475-B1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | disclosed |
| US-6605723-B2 | Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst | HOFFMAN-LA ROCHE INC. | 2003-08-12 | — | — | US | disclosed |
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2001-11-01 | — | — | US | disclosed |
| EP-1136475-A1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | GRIN1, GRIN3A, GRIN2B | EPHX1 1164/4885TP53 4650/4885KDM4E 1121/4885 |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | DHPS, QDPR, TYR | EPHX1 4496/4885TP53 4477/4885KDM4E 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.